Treatment of acute hepatitis C virus infection in HIV plus patients: Dutch recommendations for management

J. E. Arends*, F. A. E. Lambers, J. T. M. van der Meer, G. Schreij, C. Richter, K. Brinkman, Andy I. M. Hoepelman

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

16 Citations (Web of Science)

Abstract

With a rising incidence of acute hepatitis C virus (HCV) infection in patients coinfected with the human immunodeficiency virus (HIV), there is a need for evidence-based treatment recommendations. There are no randomised trials available and published studies differ with respect to design, patient characteristics and number of patients included, making a comparison between studies difficult. However, it is critical to standardise treatment for this group of patients in order to optimise the outcome of therapy. The Dutch Society for HIV Physicians proposed to write recommendations for the treatment of acute HCV in HIV-coinfected patients. Combination therapy with pegylated interferon-alpha and ribavirin is the preferred regimen initiated preferably within 12 weeks after the diagnosis of acute HCV. A treatment duration of 24 weeks is recommended in case of a favourable virological response (either achievement of a rapid virological response or a >2logio decrease plus undetectable HCV-RNA at week 12). In all other patients prolonging the duration of therapy to 48 weeks should be considered.
Original languageEnglish
Pages (from-to)43-49
JournalNetherlands Journal of Medicine
Volume69
Issue number1
Publication statusPublished - Jan 2011

Keywords

  • Acute hepatitis C
  • HIV
  • peginterferon-alfa
  • ribavirin
  • therapy

Cite this